Trevi Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRVI and other ETFs, options, and stocks.About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease.
TRVI Key Statistics
Stock Snapshot
As of today, Trevi Therapeutics(TRVI) shares are valued at $14.36. The company's market cap stands at 1.82B, with a P/E ratio of -38.16.
During the trading session on 2025-12-11, Trevi Therapeutics(TRVI) shares reached a daily high of $14.39 and a low of $12.92. At a current price of $14.36, the stock is +11.1% higher than the low and still -0.2% under the high.
Trading volume for Trevi Therapeutics(TRVI) stock has reached 4.58M, versus its average volume of 2.93M.
The stock's 52-week range extends from a low of $2.36 to a high of $14.39.
The stock's 52-week range extends from a low of $2.36 to a high of $14.39.
TRVI News
TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...
Trevi Therapeutics (TRVI) announced that David Hastings will assume the role of CFO effective January 6, 2026. Most recently, Hastings was CFO at Arbutus from J...